Navigation Links
VIVUS Reports 2010 Fourth Quarter and Full-Year Financial Results
Date:2/28/2011

results related to the MUSE business have been classified as discontinued operations.  In the fourth quarter of 2010, we reported a net loss from continuing operations of $19.1 million, or $0.23 per share, net income from discontinued operations of $12.6 million, or $0.15 per share, and total net loss of $6.5 million, or $0.08 per share.  The loss from continuing operations included a $6.0 million loss on the early extinguishment of long term debt repaid in conjunction with the MUSE sale. The net income from discontinued operations in the fourth quarter included a $13.7 million gain from the sale of MUSE.

In the fourth quarter of 2009, we had a net loss from continuing operations of $15.5 million, or $0.19 per share, net income from discontinued operations of $2.3 million, or $0.03 per share, and total net loss of $13.2 million, or $0.16 per share.  In the fourth quarter of 2009, research and development expenses included the expenses related to the preparation of the QNEXA NDA, which was filed in December 2009.

Year End ResultsFor the year ended December 31, 2010, we reported a net loss from continuing operations of $75.4 million, or $0.93 per share, net income from discontinued operations was $9.4 million, or $0.11 per share, and total net loss of $66.1 million, or $0.82 per share.  As mentioned above, in the fourth quarter of 2010 we closed the sale of MUSE.  We included in the net loss from continuing operations a $6.0 million loss on the early extinguishment of long term debt repaid in conjunction with the MUSE sale and recorded a $13.7 million gain from the sale of MUSE, which is included in the net income from discontinued operations.  Also included in the results from continuing operations in 2009 is $31.4 million in revenue, previously deferred, from the sale of Evamist.  

Cash, Cash Equivalents and Available-for-Sale SecuritiesVIVUS had cash, cash equivalents and available-for-sale securities (
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Results From Phase 3 EQUATE Trial of VIVUS Qnexa Highlighted at European Congress on Obesity
2. VIVUS Initiates Open Label Safety Study of Avanafil for Erectile Dysfunction
3. Data on VIVUS Qnexa to be Featured at European Association for the Study of Diabetes Annual Meeting
4. VIVUS Announces Promotion of Peter Tam to President
5. VIVUS to Present at Lazard Capital Markets Healthcare Conference
6. VIVUS Submits Qnexa(R) New Drug Application to the FDA for the Treatment of Obesity
7. VIVUS to Host Conference Call and Webcast Discussion of Avanafil Phase 3 Results
8. VIVUS Announces Sale of MUSE Assets to Meda
9. FDA Issues Complete Response Letter to VIVUS Regarding New Drug Application for QNEXA®
10. VIVUS Reports Third Quarter and First Nine Months 2010 Financial Results
11. VIVUS to Present at Two Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... , Sept. 2, 2014 /PRNewswire-iReach/ -- Ortho Development® ... Alpine™ Hip Stem, the latest addition to its ... Stem is intended for use in total hip ... http://photos.prnewswire.com/prnh/20140830/141676 Alpine was ... stem philosophy. ODEV,s engineers worked closely with a ...
(Date:9/2/2014)... September 2, 2014 Today, Analysts ... WLP ), Tekmira Pharmaceuticals Corporation (NASDAQ: ... ), Sanofi SA (NYSE: SNY ) and ... notes ahead of publication. To reserve complementary membership, limited ... ,WellPoint Inc. Research Reports ,WellPoint Inc. (WellPoint) posted on ...
(Date:9/2/2014)... , Sept. 2, 2014 /PRNewswire-iReach/ -- The Australian ... universal healthcare coverage and good access to facilities ... and its associated disease burden, well-defined regulatory guidelines, ... of a new manufacturing policy will drive the ... a focus on generic substitution and price cuts ...
Breaking Medicine Technology:Ortho Development Receives FDA Clearance for Alpine Hip Stem 2Upcoming Event, Positive Findings, Regulatory Approvals, and Vaccine License - Research Reports on WellPoint, Tekmira, Zoetis, Sanofi and GSK 2Upcoming Event, Positive Findings, Regulatory Approvals, and Vaccine License - Research Reports on WellPoint, Tekmira, Zoetis, Sanofi and GSK 3Upcoming Event, Positive Findings, Regulatory Approvals, and Vaccine License - Research Reports on WellPoint, Tekmira, Zoetis, Sanofi and GSK 4Upcoming Event, Positive Findings, Regulatory Approvals, and Vaccine License - Research Reports on WellPoint, Tekmira, Zoetis, Sanofi and GSK 5Upcoming Event, Positive Findings, Regulatory Approvals, and Vaccine License - Research Reports on WellPoint, Tekmira, Zoetis, Sanofi and GSK 6Australia Medical Devices Market worth $10.4 billion by 2020 Says a New Report Available at MarketOptimizer.org 2Australia Medical Devices Market worth $10.4 billion by 2020 Says a New Report Available at MarketOptimizer.org 3Australia Medical Devices Market worth $10.4 billion by 2020 Says a New Report Available at MarketOptimizer.org 4Australia Medical Devices Market worth $10.4 billion by 2020 Says a New Report Available at MarketOptimizer.org 5
... YORK, Dec. 23, 2010 Dr. David Samadi, robotic ... of Urology, and Chief of Robotics and Minimally Invasive Surgery ... continues to break barriers by sharing his robotic surgery ... worldwide. Today, Samadi, a pioneer surgeon in the field of ...
... 23, 2010 Generex Biotechnology Corporation ( www.generex.com ) (OTC ... to extend the closing date of its previously announced acquisition ... www.globalmeddirect.com ) to June 1, 2011. The Company ... decision of the Nasdaq Listing and Hearing Review Council affirming ...
Cached Medicine Technology:Robotic Surgery Expert Dr. David Samadi, MD Travels to Israel to Perform a Live Robotic Prostatectomy 2Robotic Surgery Expert Dr. David Samadi, MD Travels to Israel to Perform a Live Robotic Prostatectomy 3Generex Announces Extension of Global Medical Direct Acquisition Closing Date 2Generex Announces Extension of Global Medical Direct Acquisition Closing Date 3
(Date:9/2/2014)... patient adherence to treatment following a myocardial infarction ... results reported at the European Society of Cardiology,s ... Principal Investigator Valentin Fuster, MD, PhD, Director of ... at Mount Sinai and General Director of the ... in Madrid, Spain, the novel fixed-dose combination drug ...
(Date:9/2/2014)... Obesity is associated with many health risks, including heart ... found a possible way to mitigate one often-overlooked risk: ... study led by Sheldon H. Jacobson, a professor of ... obesity rates are associated with a decrease in seatbelt ... laws are in effect. , "Primary seatbelt laws lead ...
(Date:9/2/2014)... Betmiga) has been approved since December 2012 for the ... benefit assessment pursuant to the Act on the Reform ... Institute for Quality and Efficiency in Health Care (IQWiG) ... over the appropriate comparator therapy specified by the Federal ... regard to side effects: Dry mouth was less common ...
(Date:9/2/2014)... (PRWEB) September 02, 2014 Welcome to ... the over 4.6 million Canadians living with the disease, ... “Voices of Arthritis” video series featuring well-known Canadians from ... ,      Lloyd Robertson , veteran news ... silver medal skier ,      Amy Cotton ...
(Date:9/2/2014)... has become an increasing concern to health officials both ... City Department of Health and Mental Hygiene, the number ... triple the number of such deaths in 2000. Much ... rise in nonmedical prescription opioid (PO) use among teens ... among youth who transitioned from POs to heroin. ...
Breaking Medicine News(10 mins):Health News:New polypill increases heart attack patients' medication adherence 2Health News:New polypill increases heart attack patients' medication adherence 3Health News:Seatbelt laws encourage obese drivers to buckle up 2Health News:Mirabegron for overactive bladder: Added benefit not proven 2Health News:Mirabegron for overactive bladder: Added benefit not proven 3Health News:‘Voices of Arthritis’ Launches Awareness Month 2Health News:‘Voices of Arthritis’ Launches Awareness Month 3Health News:NYC teens and young adults who abuse prescription at high risk for overdose 2Health News:NYC teens and young adults who abuse prescription at high risk for overdose 3
... John Brumby today announced a $100 million (AUD) ... supercomputer facility to assist in discovering cures and ... brain disorders and ,flu pandemics. , In making ... at UC San Diego, Premier Brumby said the ...
... RICHMOND, Calif., June 18 Transcept,Pharmaceuticals, Inc. today ... Officer, will present at the Jefferies 2nd Annual,Healthcare ... 25, 2008 at 9:30,AM Eastern Time., The ... http://www.wsw.com/webcast/jeff26/transcept ., About Transcept Pharmaceuticals, Transcept ...
... Accuray,Incorporated (Nasdaq: ARAY ), a global leader ... and chief executive officer, Euan S.,Thomson, Ph.D., is scheduled ... 26, 2008 at 10:15 a.m. EDT (7:15 a.m. PDT)., ... available online from the,investor relations page of the Company,s ...
... 18 The Quantum Group,Inc. (Amex: QGP ) ... for the second quarter of fiscal 2008 ended April ... 2008, the Company reported an increase,in revenues of approximately ... of fiscal year 2007. On a sequential basis compared ...
... FORT LAUDERDALE, Fla., June 18 eDiets.com,Inc. (Nasdaq: ... to bring diet,fitness and healthy lifestyle solutions to ... Information Officer effective immediately.,Bringing over 8 years of ... as the CIO and VP of IT at ...
... leader in,providing automated, molecular testing solutions, announced today ... for Human papillomavirus. Patent No.1,499 749 B1, "Human ... method for detecting the presence of HPV using ... of our collaboration with Dr. Erik,Thunnissen, a prominent ...
Cached Medicine News:Health News:Premier Brumby announces plans to build largest life sciences supercomputer facility 2Health News:Premier Brumby announces plans to build largest life sciences supercomputer facility 3Health News:Transcept Pharmaceuticals to Present at the Jefferies 2nd Annual Healthcare Conference 2Health News:Accuray Incorporated's CEO to Speak at Jefferies Second Annual Healthcare Conference 2Health News:The Quantum Group Announces Second Quarter Financial Results for Fiscal Year 2008 2Health News:The Quantum Group Announces Second Quarter Financial Results for Fiscal Year 2008 3Health News:The Quantum Group Announces Second Quarter Financial Results for Fiscal Year 2008 4Health News:eDiets.com(R) Appoints New Chief Information Officer Laura Klein 2Health News:eDiets.com(R) Appoints New Chief Information Officer Laura Klein 3
... The 8600 Series Tabletop/Portable Digital ... universal tool for patient monitering. ... monitoring, the 8600 has earned ... worldwide and is recognized for ...
Halogen-free immersion oil based on ester oil....
Immersion oil composed on polyester polyol, diphenyl cresyl phosphate and tricyclodecane dimethanol....
Immersion oils may crystallize on storage. Can be redissolved on heating to 50ºC (1-2 hours)...
Medicine Products: